It is not clear how the formation of various HER receptors’ homo- and heterodimers impact the function of trastuzumab in HER2-mediated cell signaling, and how this is related to the efficacy of trastuzumab in treating breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.